

2 December 2025

BXN strengthens financial leadership with key CFO appointment

Bioxyne Limited (ASX: BXN) (“Bioxyne” or “the Company”) is pleased to announce the appointment of Mr. Paul Mitchell as Chief Financial Officer of its wholly owned subsidiary, Breathe Life Sciences Pty Ltd (BLS).

This strategic appointment strengthens financial leadership at a pivotal time as BXN continues the rapid growth trajectory validated by its recent ranking among Australia’s 15 fastest-growing companies in the 2025 Deloitte Technology Fast 50.

Mr Mitchell brings over 25 years of senior financial and transactional experience, with deep expertise in strategic planning, complex M&A, scaling high-growth businesses, implementing enterprise-wide ERP systems, and hands-on pharmaceutical manufacturing in regulated environments.

Most recently, Mr. Mitchell was Head of Corporate Development at Unitywater, and previous roles include CFO of Custodian Funds Management, Partner in Transactions & Restructuring at KPMG Hong Kong, and senior finance positions at Herron Pharmaceuticals and Energex. With a proven record of driving both organic and inorganic growth.

In this new role, Mr. Mitchell will oversee financial strategy and operations for BLS in Australia and the UK. Importantly he will lead the design and implementation of a new group-wide ERP system to support the company’s rapid scaling across GMP manufacturing, import/export, and distribution of controlled medicines — including medicinal cannabis, psilocybin, and MDMA.

Chief Executive Officer Sam Watson commented:

“We are thrilled to welcome Paul to Bioxyne team. His proven expertise in pharmaceutical manufacturing within highly regulated environments, combined with his M&A and systems implementation experience, makes him ideally suited to drive our ambitious international manufacturing and commercialisation strategy.”

Chief Financial Officer of Bioxyne Limited, Guy Robertson, added:

“Paul’s appointment is perfectly timed. With BLS now operating across Australia, the UK, and Europe, he brings the financial discipline, strategic planning capability, and hands-on ERP leadership required to support the powerhouse that is Breathe Life Sciences. I look forward to working closely with him as we build a world-class finance function to match our operational momentum.”

Mr Mitchell holds an MBA and Bachelor of Commerce/Economics from the University of Queensland, is a member of the Institute of Chartered Accountants ANZ and a Graduate of the Australian Institute of Company Directors.

Approved by the Board of Bioxyne Limited for release to the ASX.



info@bioxyne.com



+61 2 9078 8180



Suite 506, Level 5 50 Clarence
Street, Sydney NSW 2000

For further information, please contact:

Bioxyne Limited

Sam Watson
Chief Executive Officer
info@bioxyne.com

NWR Communications

Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au

About Bioxyne Limited

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.

About Breathe Life Sciences

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, health products, and prescription-only cannabis medicines.
- b) Contract drug manufacturing and white label manufacturing of scheduled medicines, therapeutic goods, medical devices, consumer health products, and active pharmaceutical ingredients. BLS manufactures over 200 of Australia’s medicinal cannabis brands.
- c) Import, export, and wholesale of active pharmaceutical ingredients, starting materials, patient-ready medicinal products, and/ or consumer health products in Australia, Japan, UK, USA and Europe.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - United Kingdom: drwatsoncbd.com
 - UK / EU: breathelifesciences.com

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com